This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Chapman, D. F. Articles by Zivin, J. Search for Related Content PubMed PubMed Citation Articles by Chapman, D. F. Articles by Zivin, J. Pubmed/NCBI databases Substance via MeSH Medline Plus Health Information Stroke Related Collections Acute Cerebral Infarction Embolic stroke Thrombolysis

(Stroke. 2001;32:748.)
© 2001 American Heart Association, Inc.

Original Contributions

Comparison of TNK With Wild-Type Tissue Plasminogen Activator in a Rabbit Embolic Stroke Model

Deborah F. Chapman, MSc; Patrick Lyden, MD; Paul A. Lapchak, PhD; Sonia Nunez, BA; Harold Thibodeaux, BS Justin Zivin, MD, PhD

From the Department of Neurosciences, University of California at San Diego School of Medicine, and Department of Neurology, Veterans Administration Medical Center, San Diego, Calif.

Correspondence to Dr Patrick Lyden (127), 3350 La Jolla Village Dr, San Diego, CA 92161. E-mail Plyden{at}ucsd.edu

Background and Purpose—Tissue plasminogen activator (tPA) is an effective treatment for stroke, but its utility is limited by fear of cerebral hemorrhage. Tenecteplase (TNK), a genetically modified form of wild-type tPA, exhibits a longer biological half-life and greater fibrin specificity, features that could lead to fewer cerebral hemorrhages than wild-type tPA in stroke patients.

Methods—We injected radiolabeled blood clots into the cerebral circulation of New Zealand White rabbits. One hour later, we administered tPA (n=57), 0.6 mg/kg TNK (n=43), 1.5 mg/kg TNK (n=27), or vehicle control (n=37). A blinded observer examined the brains for macroscopic hemorrhage using a semiquantitative score. We estimated thrombolysis by assessing the amount of radiolabel remaining in the cerebral vessels postmortem.

Results—Both wild-type tPA and TNK caused thrombolysis in most subjects. Hemorrhage was detected in 26% (6/23) of the control group, 66% (27/41) of the wild-type tPA group, 55% (16/29) in the 0.6-mg/kg TNK group, and 53% (9/17) in the 1.5-mg/kg TNK group (P<0.05, ² test). The tPA group was statistically significantly different from the control group, but the TNK and tPA groups did not differ from each other. Neither TNK nor tPA affected the size of the hemorrhages.

Conclusions—TNK shows comparable rates of recanalization compared with wild-type tPA in a model of embolic stroke. While tPA increases hemorrhage rate, the hemorrhage associated with TNK treatment is not statistically different compared with controls or the tPA group. These findings suggest that TNK shows promise as an alternative thrombolytic treatment for stroke, but we could not demonstrate improved safety compared with wild-type tPA.

Key Words: cerebral embolism • hematoma • hemorrhage • thrombolysis • thrombolytic therapy • rabbits

This article has been cited by other articles:

				P. A. Lapchak, M.-K. Han, K. F. Salgado, J. Streeter, and J. A. Zivin Safety Profile of Transcranial Near-Infrared Laser Therapy Administered in Combination With Thrombolytic Therapy to Embolized Rabbits Stroke, November 1, 2008; 39(11): 3073 - 3078. [Abstract] [Full Text] [PDF]

				M. G. Lansberg, J. D. Fields, G. W. Albers, M. V. Jayaraman, H. M. Do, and M. P. Marks Mechanical Thrombectomy Following Intravenous Thrombolysis in the Treatment of Acute Stroke Arch Neurol, November 1, 2005; 62(11): 1763 - 1765. [Abstract] [Full Text] [PDF]

				J. A. Zivin Perfusion-Weighted Imaging/Diffusion-Weighted Imaging Mismatch on MRI Can Now Be Used to Select Patients for Recombinant Tissue Plasminogen Activator Beyond 3 Hours: Con Stroke, May 1, 2005; 36(5): 1099 - 1100. [Full Text] [PDF]

				E. C. Haley Jr, P. D. Lyden, K. C. Johnston, T. M. Hemmen, and the TNK in Stroke Investigators A Pilot Dose-Escalation Safety Study of Tenecteplase in Acute Ischemic Stroke Stroke, March 1, 2005; 36(3): 607 - 612. [Abstract] [Full Text] [PDF]

				T. Nassar, S.'e. Akkawi, A. Shina, A. Haj-Yehia, K. Bdeir, M. Tarshis, S. N. Heyman, and A. A.-R. Higazi In vitro and in vivo effects of tPA and PAI-1 on blood vessel tone Blood, February 1, 2004; 103(3): 897 - 902. [Abstract] [Full Text] [PDF]

				M. Fisher Recommendations for Advancing Development of Acute Stroke Therapies: Stroke Therapy Academic Industry Roundtable 3 Stroke, June 1, 2003; 34(6): 1539 - 1546. [Abstract] [Full Text] [PDF]

				P. A. Lapchak, D. M. Araujo, S. Pakola, D. Song, J. Wei, and J. A. Zivin Microplasmin: A Novel Thrombolytic That Improves Behavioral Outcome After Embolic Strokes in Rabbits Stroke, September 1, 2002; 33(9): 2279 - 2284. [Abstract] [Full Text] [PDF]